Skip to Content

CymaBay Therapeutics Inc CBAY

Morningstar Rating
$32.23 +0.04 (0.12%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

CBAY is trading at a 36% premium.
Price
$32.13
Fair Value
$23.61
Uncertainty
Very High
1-Star Price
$19.19
5-Star Price
$58.93
Economic Moat
Dvkm
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CBAY is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$32.19
Day Range
$32.1932.35
52-Week Range
$7.2632.35
Bid/Ask
$32.18 / $32.30
Market Cap
$3.70 Bil
Volume/Avg
3.5 Mil / 4.2 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
110.16
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

CymaBay Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing therapies for patients with liver and other chronic diseases with high unmet medical need. Its product in pipeline includes two clinical stage product candidates: seladelpar (a PPARd agonist) and MBX-2982 (a GPR119 agonist).
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
63

Comparables

Valuation

Metric
CBAY
DYN
MORF
Price/Earnings (Normalized)
Price/Book Value
12.5111.752.82
Price/Sales
110.163,216.44
Price/Cash Flow
Price/Earnings
CBAY
DYN
MORF

Financial Strength

Metric
CBAY
DYN
MORF
Quick Ratio
10.705.3228.43
Current Ratio
10.965.6728.94
Interest Coverage
−5.27
Quick Ratio
CBAY
DYN
MORF

Profitability

Metric
CBAY
DYN
MORF
Return on Assets (Normalized)
−30.06%−70.31%−19.79%
Return on Equity (Normalized)
−51.97%−86.14%−20.47%
Return on Invested Capital (Normalized)
−30.87%−78.80%−23.98%
Return on Assets
CBAY
DYN
MORF
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRRjlsh$550.4 Bil
VRTX
Vertex Pharmaceuticals IncHpbblr$111.8 Bil
REGN
Regeneron Pharmaceuticals IncYjcqpm$107.9 Bil
MRNA
Moderna IncTcts$36.3 Bil
ARGX
argenx SE ADRPvyw$23.0 Bil
BNTX
BioNTech SE ADRMnt$21.6 Bil
ALNY
Alnylam Pharmaceuticals IncBtxsl$19.2 Bil
BMRN
Biomarin Pharmaceutical IncHftdwhh$16.4 Bil
RPRX
Royalty Pharma PLC Class AHtntvdy$13.4 Bil
INCY
Incyte CorpMpfxzfl$13.3 Bil

Sponsor Center